{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5","upperLimit":"3021","value":"125"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"description":"The duration of ARQ 197 exposure in this study was calculated as \\[(date of last dose of study drug - date of first dose of study drug) + 1\\]. Results refer to duration of ARQ 197 treatment in the present study only (i.e., does not include treatment received during participation in \"feeder\" studies).","dispersionType":"Full Range","groups":[{"description":"Participants received tivantinib 360 mg twice daily by mouth as monotherapy or combination therapy.","id":"OG000","title":"Tivantinib (Monotherapy or Combination)"}],"paramType":"MEDIAN","populationDescription":"All participants who received ≥1 dose of study drug are included.","reportingStatus":"POSTED","timeFrame":"Up to 3,021 days (up to 14-Jan-2019)","title":"Extent of Exposure to ARQ 197 in Participants Benefiting From Prior ARQ 197 Therapy","type":"PRIMARY","unitOfMeasure":"Days"}